Abstract: OBJECTIVE: This study was undertaken to test injectable surgical sealants that are biocompatible with fetal membranes and that are to be used eventually for the closure of iatrogenic membrane defects. STUDY DESIGN: Dermabond (Ethicon Inc, Norderstedt, Germany), Histoacryl (B. Braun GmbH, Tuttlingen, Germany), and Tissucol (Baxter AG, Volketwil, Switzerland) fibrin glue, and 3 types of in situ forming poly(ethylene glycol)-based polymer hydrogels were tested for acute toxicity on direct contact with fetal membranes for 24 hours. For the determination of elution toxicity, extracts of sealants were incubated on amnion cell cultures for 72 hours. Bonding and toxicity was assessed through morphologic and/or biochemical analysis. RESULTS: Extracts of all adhesives were nontoxic for cultured cells. However, only Tissucol and 1 type of poly(ethylene glycol)-based hydrogel, which is a mussel-mimetic tissue adhesive, showed efficient, nondisruptive, nontoxic bonding to fetal membranes. Mussel-mimetic tissue adhesive that was applied over membrane defects that were created with a 3.5-mm trocar accomplished leak-proof closure that withstood membrane stretch in an in vitro model. CONCLUSION: A synthetic hydrogel-type tissue adhesive that merits further evaluation in vivo emerged as a potential sealing modality for iatrogenic membrane defects. DOI: https://doi.org/10. 1016/j.ajog.2009.07.051 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-29861 Accepted Version Originally published at: Bilic, G; Brubaker, C; Messersmith, P B; Mallik, A S; Quinn, T M; Haller, C; Done, E; Gucciardo, L; Zeisberger, S M; Zimmermann, R; Deprest, J; Zisch, A (2010 Iatrogenic preterm premature rupture of the fetal membranes is the 'Achilles heel' of fetoscopic interventions for prenatal surgery. Recent efforts have concentrated to take action before rupture rather than to react after obvious or symptomatic rupture. Along this lines, we introduce a novel injectible material sealant for fetal membrane repair that possesses appealing characteristics for preventive closure of fetoscopic entry sites. We show that this material is capable of sealing 3.5 mm trocar punctures in fetal membranes ex vivo.
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Introduction
Invasive diagnostic and therapeutic fetal procedures are frequently complicated by amniotic fluid leakage, separation of amnion and chorion, or even frank iatrogenic preterm premature rupture of the fetal membranes (iPPROM). For fetoscopic procedures, rates of iPPROM range between 6 to 45%, 1 but in a trial of fetal endoscopic tracheal occlusion for severe congenital diaphragmatic hernia a 100% rate was reported. 2 Since these procedures are usually performed in the second trimester of pregnancy, iPPROM usually occurs at an early gestational age. Hence, the associated morbidity and mortality may compromise the expected benefits of the intervention. iPPROM is therefore a serious limitation for prenatal fetal surgery. Clinically, measures of plugging membranes after established rupture as well as of preventive plugging of fetoscopic access sites have been undertaken, as reviewed before.
3,4
For closure after obvious iatrogenic rupture, intra-amniotic injection at the puncture site of maternal platelets mixed with fibrin cryoprecipitate ('amniopatch') has evolved as promising route to seal. 5, 6 But increasing efforts have been concentrated on taking action before rupture rather than reacting after established or symptomatic rupture. Several preventive plugging methods using dry collagen and gelatin plugs or liquid blood-derived sealants have already been clinically investigated. Early experience encourages this avenue for prevention of iPPROM. A 2006 report on a 27 patient cohort found a low 4.2% rate of postoperative PPROM upon gelatin plug (Gelfoam) insertion upon port retrieval in endoscopic fetal surgery. 7 In another small clinical study, sequential injection of platelets, fibrin glue and powdered collagen slurry directly to the puncture site successfully prevented amniotic fluid loss after endoscopic procedure. 8 Still, the positive outcome with these methods await to be reproduced in other centers. Of note, collagen fleece plugs (Lyostypt) are now routinely used for preventive plugging of membrane defects following fetoscopic endoluminal tracheal occlusion for in utero therapy of congenital diaphragmatic hernia in one center of the authors, 10 Further, laser welding, and pre-emptive placement of synthetic surgical sealants before fetoscopic access were evaluated in vitro. 11, 12 There is evidence that spontaneous healing is slow, if not absent in fetal membranes. Histological follow-up of fetoscopic puncture defects in membranes of human patients several months after the procedure showed that the defects did not close by healing. 13 The amnion layer contains few cells and lacks blood vessels completely, which makes healing response in this layer unlikely. Our own trials in rabbits of prophylactic plugging of membrane defects with decellularized amnion scaffolds showed effective sealing but without detectable signs of biological repair after a 1-week period, 9 which is the maximum achievable in this experimental model. Recent studies in the midgestational rabbit observed signs of beginning healing of membrane defects upon addition of platelets or amniotic fluid cells to collagen plugs; 14,15 the jury is still out whether this effect could assume relevant degrees of healing long-term. The main criteria for a prophylactic plug material may be to present an immediate, non-toxic and ideally, durable physical barrier to amniotic fluid, and not necessarily induction of biological healing. With this strategy in mind, we examined five liquid synthetic sealants, namely two types of cyanoacrylate glues and three poly (ethylene glycol-based) hydrogel-type polymers, for their principal aptitude for fetal membrane repair. Gluing of defective tissue in moist/wet conditions or even underwater presents a particular challenge. In the present study, we addressed gluing to moist, intact fetal membranes. Alkyl-cyanoacrylate glues were chosen on the basis of their well-known strong bonding to tissue, and their use as tissue adhesives in surgical and traumatic wound repair. 16 Our choice of three synthetic poly (ethylene glycol) (PEG)-based hydrogel sealants, photopolymerizable gel, mussel-mimetic adhesive and commercial SprayGel was based on data showing their interfacial bonding to various tissues, and the possibility to deliver them in 7 minimally invasive liquid form for gelation in situ. [17] [18] [19] Two types of PEG-based hydrogels under present study, SprayGel and photopolymerized PEG, were already used clinically.
SprayGel has been clinically used as bioabsorbable anti-adhesion barrier in patients undergoing myomectomy. 20 A clinically approved formulation of photopolymerized PEG hydrogel sealant, FocalSeal-L sealant, proved successful for closure of pulmonary air leaks in the lung occuring at cardiac operations. 21 For the experimental mussel-mimetic adhesive hydrogel formulation of present study, no clinical data exist yet. Here we estimated applicability of these synthetic polymers as sealants on fetal membranes based on their bonding to fetal membranes and toxicity in vitro, using the biosurgical Tissucol fibrin glue sealant as internal reference.
Material and methods
Membrane collection and amnion cell isolation
The Histoacryl are marketed as topical skin adhesives to hold skin edges of wounds from surgical incisions. As specified by the manufacturer of Dermabond, it is not for application on wet wounds.
Hydrogel sealants:
SprayGel (Confluent Surgical, Inc., Waltham, MA) is a sprayable anti-adhesion barrier polymer that consists of two synthetic liquid precursors that when mixed together, rapidly cross-link to form a solid absorbable hydrogel in situ. The first precursor is a modified polyethelene glycol (PEG) with terminal electrophilic esters groups while the other precursor solution contains PEG that has nucleophilic amine groups. 22 SprayGel is marketed outside the US for use in abdominal and pelvic surgical procedures. It has been clinically also tried to reduce adhesion formation after ovarian surgery. 19 SprayGel was deposited at the fetal membranes through the air pump-assisted SprayGel Laparoscopic Sprayer. The gel is formulated to remain adherent on the site of application for approximately five days whereafter it is absorbed by way of gradual hydrolysis.
Photopolymerized PEG hydrogel sealant (pPEG) was formed via in situ interfacial photopolymerization of PEG diacrylate precursor of average molecular weight 700 Da (Sigma) according to a previously described gelation protocol. 18 Fetal membranes were flushed with a tissue adsorbing photoinitiator eosin Y (1mM in 10mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, pH 7.4, 0.15M sodium chloride; (HEPESbuffered saline). Then solution containing 10% PEG diacrylate and the co-catalysts triethanolamine (13.2 µL/mL) and 1-vinyl-2-pyrrolidine (3.5µL/mL) in HEPES-buffered 9 saline was applied to the membranes and photopolymerized by irradiation at 480-520 nm and 75mW/cm 2 for 1 min from a portable Cermax xenon fiber optic light source, CXE300 (ILC Technology Inc., USA).
The mussel-mimetic tissue sealant is a catechol-functionalized poly(ethylene glycol) (cPEG) whose molecules crosslink into a hydrogel by way of oxidation after addition of sodium periodate. 23 The composition and synthesis of cPEG is described elsewhere. 24 For gelation, equal volumes of the polymer precursor solution (300 mg/mL in phosphate-buffered saline (PBS)) and the cross-linking solution (12 mg/mL sodium periodate in water) were mixed using a dual syringe applicator device equipped with a blending connector with mixer (FibriJet; Micromedics, Inc., St. Paul, MN). Hydrogels prepared from cPEG polymer and its derivatives are expected to possess the ability to secure very strong adhesion to almost any surface, even under wet conditions. The presence of catechol in cPEG sealant was inspired by the wet adhesive properties conferred by the catechol side chain of 3,4-dihydroxyphenylalanine (DOPA) amino acid, which is found in high concentrations in the foot proteins of marine or freshwater mussels. 25, 26 Tissucol Duo S fibrin glue (Baxter AG, Volketwil, Switzerland) is a biological two- 
Toxicity tests
Toxicity of sealants for fetal membrane cells was evaluated using direct contact and elution tests, as per International Organization for Standardization (ISO) 10993-5 guidelines.
Direct contact cytotoxicity:
10 Direct contact studies were performed with term fetal membranes obtained from three cases.
The amniotic layer was chosen for sealant application (Fig. 1A) because this layer was proposed to be the strength-bearing layer of fetal membranes and major determinant for PPROM. 28 2x1cm patches of freshly harvested fetal membranes were placed into wells of 6-well plates with amnion layer up. The sealants were applied at 50µl and 200µl volumes except cPEG adhesive which was only tested at 200µl volume because of limited material.
Membranes covered with sealant were covered with 3 mL culture medium (Ham's F-12/DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin) and cultured for 24h at 37°C. Controls were untreated membranes that were immediately processed for histology (control '0') or cultured for 24h (control '24'). After 24h, the treated membranes were fixed in 4% formaline, embedded in paraffin and sectioned for histology.
Deparaffinized sections were either stained with hematoxylin-eosin (H/E), or stained for 
Sealing of fetal membranes lesion in vitro
Sealing performance of cPEG adhesive was tested on trocar punctures through fresh fetal membranes. For that, wet fetal membranes were flat-mounted with the amnion side up on a commercial motorized mechanical stretch device named 'The Cellerator' (Cytomec GmbH, Switzerland; http://www.cytomec.com/) that we further adapted for use in fetal membrane studies (Fig. 4A) . The Cellerator device permits fetal membranes expansion in a radial fashion keeping the strength of stretch uniformly distributed along the mounted membrane.
Puncture lesions were created with a three-side pointed Ø 3.5mm trocar (Richard Wolf GmbH, Knittlingen, Germany). The punctured membranes were kept moistened with excess PBS, before approximately 0.5 mL cPEG adhesive was applied over the membrane defect.
Two minutes after treatment, membranes were further stretched by about 30% of their original area. To demonstrate leak-proof sealing, the membranes, still mounted in the device, were overlaid with 0.3 L water. After the leak-proof test, the area of the treated membrane defect was excised and processed for standard histology. Histologic sealing was estimated microscopically from hematoxylin/eosin stained sections by the ability of the sealant to form a continuous bridge between the wound edges.
Statistical analysis
Data are shown as mean ± SEM. Two-tailed unpaired t test was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). Significance level was set at p< 0.05.
Results
Contact-mediated effect of sealants for membrane morphology
Histology in figure 1 illustrates the effect of treatment for overall membrane morphology for the six bioadhesives under test. Fibrin glue and cPEG adhesive formed a continuous layer tightly bound to tissue ( Figure 1B, arrow heads) . The normal membrane morphology appeared maintained, with the amnion epithelial layer intact. SprayGel and pPEG exhibited partial or no binding to tissue, respectively. In the case of pPEG, we found the hydrogel layer sloughed into the culture medium shortly after immersion of the membranes in culture medium. Binding of Dermabond and Histoacryl to fetal membranes resulted in disruption of the amnion layer and change of overall membrane morphology, which was more pronounced for Dermabond. The effects of 50µl treatment volumes were very similar (not shown). Fig. 2B gives the apoptosis rates for the 200µl test series. In untreated reference membranes, the apoptosis rate increased to 17±2% during the 24h incubation. Treatment with fibrin glue, cPEG adhesive, and pPEG did not enhance apoptosis over control. Dermabond and SprayGel treatment significantly (p< 0.05) enhanced apoptosis by 3.9-fold to 69±13 % and by 1.9-fold to 34±3% over the control, respectively. Histoacryl treatment produced a 1.6-fold increase of apoptosis rate to 28±6%, which was not significant over control. The outcome in the 50µl test series was similar, except that at lower dose, the apoptosis rate by SprayGel was not significantly over control (Fig. 2C ).
Direct contact-induced apoptosis
Elution toxicity of sealants for primary cultures of amnion cells
14
To test for toxicity from compounds released from the sealants, we investigated cell lysis, cell detachment and change of cell shape in hAECs and hAMCs that were grown in extracts of sealants in culture medium. None of the cultures, except those grown in extracts of Dermabond, appeared affected by toxic compounds after 24h and 72h. There was no difference between extracts prepared from sealant alone, or from sealants applied to membranes. 
Sealing of puncture lesions in vitro
Our stratification revealed that cPEG adhesive and Tissucol fibrin glue alike show strong bonding to fetal membranes and behave non-toxic, which are two basic prerequisites for prospective application for repair. cPEG adhesive is a new formulation that has never been tested for sealing of membrane defects before. We tested 0.5 mL cPEG adhesive for closure of Ø 3.5mm trocar puncture wounds in fetal membranes mounted in a biomechanical test device (Fig. 4) . Successful closure was achieved in all three test cases. Application of cPEG tissue adhesive over the defect resulted in an immediate leak-proof membrane seal that remained functional upon further radial stretch of the membranes. Membrane bonding properties of the six bioadhesives under this study demonstrated large variability. Cyanoacrylate-based glues seem inappropriate for application on fetal membranes. The observation of their strong bonding to fetal membrane tissue was accompanied by obvious damage to the amnion epithelial layer and disruption of membrane structure, especially the amnion layer. Amniotic integrity is considered more important than chorionic integrity because the amnion is thought to have greater tensile strength. 28 In addition, Dermabond, but not Histoacryl, exhibited significant cytotoxicity. Two of the PEGbased hydrogel polymers, photopolymerizable PEG hydrogel and SprayGel, failed to bond to fetal membranes sufficiently. Photopolymerized PEG-diacrylate hydrogels were previously used to create thin intravascular barriers to block thrombus deposition after balloon-induced arterial injuries in animal models, and firm adhesion of the PEG-diacrylate hydrogel to arterial walls was reported. 18, 29 Although the pPEG and SprayGel hydrogels could be polymerized on fetal membranes, they sloughed off from the membranes quickly after the immersion of the membranes in culture medium. Neither the hydrogel itself nor the one minute laser irradiation required for hydrogel curing produced adverse effects for membrane integrity. In the case of SprayGel, the resulting polymer layer was not continuous, weakly bonded to membranes, and cytotoxic.
cPEG adhesive, on the other hand, displayed membrane bonding and compatibility comparable to that of Tissucol fibrin glue. cPEG adhesive is a two-component, selfcrosslinking polymer with the remarkable property to form strong and durable bonds to many surfaces even in wet environment. Creation of cPEG adhesive has been inspired by the composition of liquid adhesives secreted by marine mussels, which allow these organisms to firmly anchor themselves to any surface. The wet adherence of native mussel adhesive proteins rests on the unusual amino acid residue 3,4 dihydroxyphenylalanine (DOPA) that is present in high concentrations in the foot proteins of mussels. 25, 30, 31 Work in the group of one of the authors (P.B.M.) and other laboratories has demonstrated that the wet adherence ability of mussel foot proteins can be conferred onto synthetic polymers by way of incorporating DOPA and DOPA analogues. 17, 23, 32, 33 Indeed, previous work has demonstrated that DOPAfunctionalized PEG precursors cross-link via sodium periodate-mediated oxidation to form adhesive hydrogels with high rigidity. 23 In the present study, the cPEG polymer contains a simplified mimic of DOPA in the form of a reactive catechol group, generating a new variation of the adhesive that can be used under the same preparative conditions. 24 This formulation possesses both appealing and potentially problematic characteristics for use as fetal membrane sealant. Properties that we consider favorable are fast gelation (under a minute); very slow hydrolysis over several months, allowing for durable sealing; and excellent tissue adhesion. Recent analysis revealed that bonds formed by a mussel-mimetic adhesive between porcine dermal tissues were several times stronger than those formed by fibrin glue. 17 Possible disadvantages of the present formulation are the use of the strong oxidizing reagent sodium periodate as trigger of polymerization, which is known to be strongly irritating. However, a rapid chemical reaction ensues upon contact of periodate with pPEG, which ultimately gives rise to chemical crosslinking of the polymer but also results in reduction of periodate to less harmful oxidative species. 17 Issues of in vivo irritation and inflammatory tissue response to cPEG adhesive are addressed in another study involving the use of cPEG for transplantation of mouse islets. 24 While the results of that study, like the data reported herein, reveal favorable in vivo biocompatibility, ultimately the full effects of cPEG on uterine contractions and fetal survival and integrity will require further evaluation in the rabbit model of midgestation.
In summary, this study points to a new hydrogel formulation with appealing properties for membrane repair. Still, we are aware that such data ex vivo are limited in their ability to predict success in the in vivo situation. 
